Corcept Therapeutics Inc. Announces Positive Results From Its Proof of Concept Study Evaluating the Ability of CORLUX(R) to Mitigate Weight Gain Associated With Olanzapine

MENLO PARK, CA--(MARKET WIRE)--Jun 21, 2007 -- Corcept Therapeutics (NasdaqCM:CORT - News) today announced that preliminary top line results indicated a statistically significant reduction in weight gain in those subjects who took olanzapine plus CORLUX compared to those who took olanzapine alone in a randomized, two week, double-blind, placebo controlled, proof of concept study.